Drug Approval Rate Stagnant -- Nektar and ADVENTRX Look to Defy Odds
The Paragon Report Provides Equity Research on Nektar Therapeutics & ADVENTRX Pharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/26/11 -- Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Nektar Therapeutics (NASDAQ: NKTR) and ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX). Access to the full company reports can be found at:
While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The Company's product pipeline consists of drug candidates across a range of therapeutic areas, including oncology, pain.
ADVENTRX Pharmaceuticals is a development-stage specialty pharmaceutical company focused on in-licensing, developing and commercializing product candidates for the treatment of cancer. The company recently announced that it held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) it received in August from the FDA regarding the Company's New Drug Application (NDA) for Exelbine (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2011 - 06:16 Uhr
Sprache: Deutsch
News-ID 1049994
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Investment Services & Trading
Anmerkungen:
Diese Pressemitteilung wurde bisher 75 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Drug Approval Rate Stagnant -- Nektar and ADVENTRX Look to Defy Odds
"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
